We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-8.86%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$220M
AUM Growth
-$17M
Cap. Flow
-$6.31M
Cap. Flow %
-2.87%
Top 10 Hldgs %
36.95%
Holding
108
New
33
Increased
19
Reduced
16
Closed
31

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.56M
2
ABT icon
Abbott
ABT
+$4.95M
3
AET
Aetna Inc
AET
+$4.28M
4
ATHN
Athenahealth, Inc.
ATHN
+$4.12M
5
SHPG
Shire pic
SHPG
+$3.89M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$8.41M
2
BRKR icon
Bruker
BRKR
+$6.43M
3
TFX icon
Teleflex
TFX
+$5.58M
4
LIVN icon
LivaNova
LIVN
+$4.01M
5
NUVA
NuVasive, Inc.
NUVA
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 59.86%
2 Financials 2.04%
3 Industrials 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTWR
51
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.57M 0.71%
+50,000
New +$1.69M
DCOY
52
Decoy Therapeutics
DCOY
$2.05M
– –
0
– –
EWA icon
53
CALL
iShares MSCI Australia ETF
EWA
$1.46B
$1.45M 0.66%
75,000
-25,000
-25% -$450K
ISEE
54
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.37M 0.62%
+32,500
New +$1.66M
ANGO icon
55
CALL
AngioDynamics
ANGO
$652M
$1.23M 0.56%
+100,000
New +$1.1M
SGNT
56
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$1.09M 0.5%
+89,713
New +$1.26M
LAB icon
57
Standard BioTools
LAB
$308M
$1.01M 0.46%
+125,000
New +$902K
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$16.1B
$979K 0.45%
+7,500
New +$934K
FOLD
59
CALL
DELISTED
Amicus Therapeutics
FOLD
$845K 0.38%
+100,000
New +$708K
NXTM
60
CALL
DELISTED
NxStage Medical Inc.
NXTM
$750K 0.34%
+50,000
New +$838K
WMGIZ
61
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$734K 0.33%
586,936
+1,500
+0.3% +$1.74K
AKRX
62
DELISTED
Akorn Inc
AKRX
$671K 0.31%
28,500
– –
FOMX
63
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$665K 0.3%
102,000
– –
CPXX
64
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$607K 0.28%
+55,000
New +$180K
VNDA icon
65
Vanda Pharmaceuticals
VNDA
$295M
$564K 0.26%
+67,500
New +$554K
RCKT icon
66
Rocket Pharmaceuticals
RCKT
$379M
$555K 0.25%
18,750
+12,050
+180% +$362K
ZGNX
67
DELISTED
Zogenix, Inc.
ZGNX
$543K 0.25%
58,750
– –
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$538K 0.24%
13,250
-250
-2% -$8.59K
DMK
69
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$493K 0.22%
1,150
– –
ADYX
70
DELISTED
Adynxx Inc
ADYX
$419K 0.19%
8,524
-193
-2% -$15.4K
TNXP icon
71
Tonix Pharmaceuticals
TNXP
$194M
– –
0
– –
OCRX
72
DELISTED
Ocera Therapeutics, Inc.
OCRX
$385K 0.18%
131,000
– –
ALDX icon
73
Aldeyra Therapeutics
ALDX
$91.1M
$241K 0.11%
57,500
– –
IMMU
74
DELISTED
Immunomedics Inc
IMMU
$181K 0.08%
+72,500
New +$163K
SCPX
75
DELISTED
Scorpius Holdings, Inc.
SCPX
$167K 0.08%
+1
New +$489K
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2016 Portfolio in Review

As of Q1 2016, Pura Vida Investments held 108 positions worth $220M, down 7.2% from $237M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments's Q1 2016 filing shows 33 new, 19 increased, 16 reduced and 31 closed positions. Its largest new stake was Abbott: 125,000 shares worth $5.23M. The largest sale was Cigna, an estimated $8.41M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Financials and Industrials.

  • Pura Vida Investments's largest Q1 2016 buy was Abbott: 125,000 shares worth $5.23M.
  • Pura Vida Investments added most to Allergan plc in Q1 2016, an estimated $8.56M increase.
  • Pura Vida Investments's biggest Q1 2016 reduction was Teleflex, cutting an estimated $5.58M.
  • Pura Vida Investments fully exited Cigna in Q1 2016, selling an estimated $8.41M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $220M portfolio in Q1 2016.
  • Pura Vida Investments opened 33 new positions and closed 31 in Q1 2016.
  • Pura Vida Investments's portfolio value fell 7.2% quarter-over-quarter to $220M.

Based on Pura Vida Investments's 13F filing for Q1 2016, filed 16 May 2016.